Macrophage-based, non‑genetically modified autologous cell therapy engineered from patients' blood to treat solid tumors. Induces polyclonal neoantigen‑specific T cell and antibody responses that can eliminate treated tumors, target metastases, provide durable immunity, and function across multiple tumor types without pre‑identifying antigens.